191 related articles for article (PubMed ID: 34142235)
1. Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.
Marijt KA; Griffioen L; Blijleven L; van der Burg SH; van Hall T
Cancer Immunol Immunother; 2022 Feb; 71(2):289-300. PubMed ID: 34142235
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on TAP and its vital role in antigen presentation and cross-presentation.
Mantel I; Sadiq BA; Blander JM
Mol Immunol; 2022 Feb; 142():105-119. PubMed ID: 34973498
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.
Aladin F; Lautscham G; Humphries E; Coulson J; Blake N
Cancer Immunol Immunother; 2007 Aug; 56(8):1143-52. PubMed ID: 17143611
[TBL] [Abstract][Full Text] [Related]
4. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
[TBL] [Abstract][Full Text] [Related]
5. Identification of non-mutated neoantigens presented by TAP-deficient tumors.
Marijt KA; Blijleven L; Verdegaal EME; Kester MG; Kowalewski DJ; Rammensee HG; Stevanović S; Heemskerk MHM; van der Burg SH; van Hall T
J Exp Med; 2018 Sep; 215(9):2325-2337. PubMed ID: 30115740
[TBL] [Abstract][Full Text] [Related]
6. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
7. TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.
Barbet G; Nair-Gupta P; Schotsaert M; Yeung ST; Moretti J; Seyffer F; Metreveli G; Gardner T; Choi A; Tortorella D; Tampé R; Khanna KM; García-Sastre A; Blander JM
Nat Immunol; 2021 Apr; 22(4):497-509. PubMed ID: 33790474
[TBL] [Abstract][Full Text] [Related]
8. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
10. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
[TBL] [Abstract][Full Text] [Related]
11. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.
Seidel UJ; Oliveira CC; Lampen MH; Hall Tv
Cancer Immunol Immunother; 2012 Jan; 61(1):119-25. PubMed ID: 22116347
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
[TBL] [Abstract][Full Text] [Related]
14. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo.
Bertholet S; Goldszmid R; Morrot A; Debrabant A; Afrin F; Collazo-Custodio C; Houde M; Desjardins M; Sher A; Sacks D
J Immunol; 2006 Sep; 177(6):3525-33. PubMed ID: 16951311
[TBL] [Abstract][Full Text] [Related]
15. The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.
Ma W; Stroobant V; Heirman C; Sun Z; Thielemans K; Mulder A; van der Bruggen P; Van den Eynde BJ
J Immunol; 2019 Jan; 202(2):451-459. PubMed ID: 30559321
[TBL] [Abstract][Full Text] [Related]
16. Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.
Atzin-Méndez JA; López-González JS; Báez R; Arenas-Del Angel MC; Montaño LF; Silva-Adaya D; Lascurain R; Gorocica P
Oncol Rep; 2016 Jan; 35(1):33-42. PubMed ID: 26498650
[TBL] [Abstract][Full Text] [Related]
17. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
18. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
19. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
